Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robledo, M.
Right arrow Articles by Rojas, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robledo, M.
Right arrow Articles by Rojas, J. M.
[Cancer Research 63, 1814-1817, April 15, 2003]
© 2003 American Association for Cancer Research

Epidemiology and Prevention

Polymorphisms G691S/S904S of RET as Genetic Modifiers of MEN 2A1

Mercedes Robledo2, Laura Gil2, Marina Pollán, Arancha Cebrián, Sergio Ruíz, Marta Azañedo, Javier Benitez, Javier Menárguez and José M. Rojas3

Unidad de Biología Celular [L. G., M. A., J. M. R.] Centro Nacional de Microbiología and Servicio de Epidemiología del Cáncer [M. P.], Centro Nacional de Epidemiología, Instituto de Salud Carlos III; Centro Nacional de Investigaciones Oncológicas [M. R., A. C., S. R., J. B.]; and Hospital General Universitario "Gregorio Marañón" [J. M.], Madrid, Spain

Multiple endocrine neoplasia type 2A (MEN 2A) is associated with specific germ-line missense mutations in the RET proto-oncogene. Only a minor fraction of human disorders are simple monogenic diseases, and the identification of polymorphisms that increase susceptibility, including variations in pathological phenotypes, to human diseases is one of the key problems in medical genetics. To explore this idea, we analyzed the polymorphisms G691S (exon 11) and S904S (TCC-TCG, exon 15) of RET in 198 individuals corresponding to 35 unrelated Spanish MEN 2A families (104 patients with oncogenic MEN 2A mutation and 94 healthy relatives). We found strong cosegregation between both polymorphisms (100% Fisher’s exact test, P < 0.001) using a control population containing 653 healthy individuals (362 females and 291 males). Interestingly, we found that the homozygous for these polymorphisms were, on average, 10 years younger at diagnosis compared with heterozygous and wild-type homozygous (P = 0.037). Taken together, all these findings could indicate that the G691S and S904S variants of RET have a modifier effect on the age at onset of MEN 2A. Moreover, compared with the control population, the homozygote status was significantly more prevalent in a series of 110 sporadic thyroid carcinoma (odds ratio = 2.36), suggesting that these polymorphisms may play a role as a low penetrance risk factor.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
S. Ruiz-Llorente, C. Montero-Conde, R. L. Milne, C. M. Moya, A. Cebrian, R. Leton, A. Cascon, F. Mercadillo, I. Landa, S. Borrego, et al.
Association Study of 69 Genes in the Ret Pathway Identifies Low-penetrance Loci in Sporadic Medullary Thyroid Carcinoma
Cancer Res., October 1, 2007; 67(19): 9561 - 9567.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
K Frank-Raue, H Buhr, H Dralle, E Klar, N Senninger, T Weber, S Rondot, W Hoppner, and F Raue
Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype.
Eur. J. Endocrinol., August 1, 2006; 155(2): 229 - 236.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
Endocr. Rev., August 1, 2006; 27(5): 535 - 560.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Lesueur, A. Cebrian, M. Robledo, P. Niccoli-Sire, K.-A. Svensson, S. Pinson, J. Leyland, J. Whittaker, P. D. Pharoah, and B. A.J. Ponder
Polymorphisms in RET and Its Coreceptors and Ligands as Genetic Modifiers of Multiple Endocrine Neoplasia Type 2A
Cancer Res., January 15, 2006; 66(2): 1177 - 1180.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Sawai, Y. Okada, K. Kazanjian, J. Kim, S. Hasan, O. J. Hines, H. A. Reber, D. S.B. Hoon, and G. Eibl
The G691S RET Polymorphism Increases Glial Cell Line-Derived Neurotrophic Factor-Induced Pancreatic Cancer Cell Invasion by Amplifying Mitogen-Activated Protein Kinase Signaling
Cancer Res., December 15, 2005; 65(24): 11536 - 11544.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Cebrian, F. Lesueur, S. Martin, J. Leyland, S. Ahmed, C. Luccarini, P. L. Smith, R. Luben, J. Whittaker, P. D. Pharoah, et al.
Polymorphisms in the Initiators of RET (Rearranged during Transfection) Signaling Pathway and Susceptibility to Sporadic Medullary Thyroid Carcinoma
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6268 - 6274.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. M. Baumgartner-Parzer, R. Lang, L. Wagner, G. Heinze, B. Niederle, K. Kaserer, W. Waldhausl, and H. Vierhapper
Polymorphisms in Exon 13 and Intron 14 of the RET Protooncogene: Genetic Modifiers of Medullary Thyroid Carcinoma?
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6232 - 6236.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Lesueur, A. Cebrian, A. Cranston, J. Leyland, T. M. Faid, M. R. Clements, M. Robledo, J. Whittaker, and B. A. J. Ponder
Germline Homozygous Mutations at Codon 804 in the RET Protooncogene in Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2A Patients
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3454 - 3457.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
S Jindrichova, J Vcelak, P Vlcek, M Neradilova, J Nemec, and B Bendlova
Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic
J. Endocrinol., November 1, 2004; 183(2): 257 - 265.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Jimenez, G. T. Dang, P. N. Schultz, A. El-Naggar, S. Shapiro, E. A. Barnes, D. B. Evans, R. Vassilopoulou-Sellin, R. F. Gagel, G. J. Cote, et al.
A Novel Point Mutation of the RET Protooncogene Involving the Second Intracellular Tyrosine Kinase Domain in a Family with Medullary Thyroid Carcinoma
J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3521 - 3526.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Elisei, B. Cosci, C. Romei, V. Bottici, M. Sculli, R. Lari, R. Barale, F. Pacini, and A. Pinchera
RET Exon 11 (G691S) Polymorphism Is Significantly More Frequent in Sporadic Medullary Thyroid Carcinoma Than in the General Population
J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3579 - 3584.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. J. Cote and R. F. Gagel
Lessons Learned from the Management of a Rare Genetic Cancer
N. Engl. J. Med., October 16, 2003; 349(16): 1566 - 1568.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.